Part 1: Screening 23,000 patients with advanced, incurable or poor prognosis cancers
Screening of up to 23,000 patients who have advanced, incurable or an earlier diagnosis of a poor prognosis cancer using Comprehensive Genomic Profiling (CGP) at no cost to the patient.
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour and we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.
The genomic profiling is carried out by NATA accredited pathology laboratories.
A team of our experts review the genomic profile of the tumour with other clinical and patient information. A Molecular Oncology Board (MOB) Report provides the genomic profiling pathology report to the referring clinician, as well as potential treatments and trials for patients.
Once a patient has provided written consent to participate in CaSP, it typically takes 8-10 weeks for the referring clinician to receive the MOB report. Patients indicated as urgent by the referring clinician will be fast-tracked, with MOB reports returned in 5-6 weeks.
2: An observational cohort study of people enrolled in CaSP
CaSP does not deliver any specific intervention and is not a clinical trial. Its primary purpose is to make Comprehensive Genomic Profiling (CGP) more broadly available to people with an unmet need and to use that information to link people to potential clinical trials.
It is important that the information collected by CaSP be used to guide how CGP is implemented in Australia and to evaluate what use it provides to the community.
Part 3: Research Registry and Biobank
CaSP will establish a research registry and bioresource to facilitate the observational cohort study and provide a resource for future use including clinical trial and treatment matching, and epidemiological and public health research studies to facilitate ongoing research into cancer and its treatment.
